TY - JOUR
T1 - Novel macrocyclic and acyclic cationic lipids for gene transfer
T2 - Synthesis and in vitro evaluation
AU - Goldring, W. P. D.
AU - Jubeli, E.
AU - Downs, R. A.
AU - Johnston, A. J. S.
AU - Khalique, N. A.
AU - Raju, L.
AU - Wafadari, D.
AU - Pungente, M. D.
PY - 2012
Y1 - 2012
N2 - The synthesis and in vitro evaluation of four cationic lipid gene delivery vectors, characterized by acyclic or macrocyclic, and saturated or unsaturated hydrophobic regions, is described. The synthesis employed standard protocols, including ring-closing metathesis for macrocyclic lipid construction. All lipoplexes studied, formulated from plasmid DNA and a liposome composed of a synthesized lipid, 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC), and either 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol as co-lipid, exhibited plasmid DNA binding and protection from DNase I degradation, and concentration dependent cytotoxicity using Chinese hamster ovary-K1 cells. The transfection efficiency of formulations with cholesterol outperformed those with DOPE, and in many cases the EPC/cholesterol control, and formulations with a macrocyclic lipid (+/− 10:1) outperformed their acyclic counterparts (+/− 3:1).
AB - The synthesis and in vitro evaluation of four cationic lipid gene delivery vectors, characterized by acyclic or macrocyclic, and saturated or unsaturated hydrophobic regions, is described. The synthesis employed standard protocols, including ring-closing metathesis for macrocyclic lipid construction. All lipoplexes studied, formulated from plasmid DNA and a liposome composed of a synthesized lipid, 1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (EPC), and either 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) or cholesterol as co-lipid, exhibited plasmid DNA binding and protection from DNase I degradation, and concentration dependent cytotoxicity using Chinese hamster ovary-K1 cells. The transfection efficiency of formulations with cholesterol outperformed those with DOPE, and in many cases the EPC/cholesterol control, and formulations with a macrocyclic lipid (+/− 10:1) outperformed their acyclic counterparts (+/− 3:1).
U2 - 10.1016/j.bmcl.2012.05.080
DO - 10.1016/j.bmcl.2012.05.080
M3 - Journal article
SN - 0960-894X
VL - 22
SP - 4686
EP - 4692
JO - Bioorganic & Medicinal Chemistry Letters
JF - Bioorganic & Medicinal Chemistry Letters
IS - 14
ER -